Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2371-2380 Newer>

The Motley Fool September 21, 2005 Rich Duprey	A Shot of Reality for Chiron Novartis warns pharma it's willing to walk away from takeover bid. Does Chiron have the wherewithal to go it alone? Investors, take note.
The Motley Fool September 20, 2005 Brian Gorman	Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note.
The Motley Fool September 20, 2005 Rich Smith	ViaCell's Cancer Trial Snag The cord blood collector suffers a research setback. Investors should keep in mind that the real money-maker behind ViaCell is its ViaCord cord blood storage business.
Insurance & Technology September 16, 2005 Phil Britt	Ounce of Prevention Horizon Blue Cross Blue Shield of New Jersey is providing system physicians with the ability to prescribe medicines electronically, which should improve safety and efficiency.
IndustryWeek October 1, 2005 Bruce Vernyi	Boston Scientific Corp.: IW Best Plants Profile 2005 Most of the plant's nearly 51,500-square-feet of manufacturing space is devoted to clean-room operations, in which surgical grafts are produced in cutting, sewing, collagen-impregnating and finishing operations.
The Motley Fool September 14, 2005 Stephen D. Simpson	Orthopedic Sector Stumbles Already antsy about potential pricing, investors reacted badly to British orthopedic company Smith & Nephew's earnings guidance.
The Motley Fool September 12, 2005 Brian Gorman	Mixed Diagnosis for Bristol-Myers Positive news on two drugs is reason to celebrate, but investors may want to keep their enthusiasm in check.
BusinessWeek September 19, 2005 Arlene Weintraub	George Rathmann: Amgen's Giant The enterprising chemist guided one of biotech's first blockbusters and taught the industry how to turn lab breakthroughs into billion-dollar products.
BusinessWeek September 19, 2005	Biotech, Then and Now Amgen's George Rathmann explains how Big Pharma's role has evolved from detractor to investor, and why R&D needs more respect.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
<Older 2371-2380 Newer> Return to current articles.